On October 21, 2013, Depomed, Inc. (NASDAQ:DEPO) announced that it has sold its interests in royalty and milestone payments under its license agreements in the Type 2 diabetes therapeutic area to PDL BioPharma (NASDAQ:PDLI), Inc. for $240.5 million in cash. The interests sold include royalty and milestone payments accruing from and after October 1, 2013:
1) From Santarus (NASDAQ:SNTS) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the U.S.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|